MapMyGenome launches pharmacogenomics solution covering more than 165 drugs

MapMyGenome, a preventive genomics company, launched its pharmacogenomics solution MedicaMap on December 4, 2022, which analyses an individual's response to medicines based on genetic makeup. Currently MedicaMap analyses 165 plus US-FDA-approved drugs across 12 different specialities such as psychiatry, oncology, cardiology, and diabetology. According to a study published in ‘The Pharmacogenomics Journal,' Indians have a higher risk for medicine-induced heart-related cases compared with the West. The study also shows Indians’ varied responses to widely used medicines like warfarin, metformin, and clopidogrel. The varied response to medicines among Indians highlights the significance of creating India-specific comprehensive pharmacogenomic data.

Dr Annie Q Hasan, Founder & President, Board of Genetic Counseling India, commented, “Medicines are usually prescribed using a “one-size-fits-all” approach. But variations in individuals’ DNA lead to variations in their response to medication.” MedicaMap covering medicines like metformin, clopidogrel, warfarin, codeine, and many other medicines commonly used by Indians, gives an easy-to-read comprehensive report on medicines' toxicity and efficacy for a person, making it easier to identify alternate medicine or adjust the dosage according to an individual’s genetic profile for the prevention, diagnosis, and treatment of any health condition.

Anu Acharya, CEO, MapMyGenome said, "MedicaMap is affordable, non-invasive, and once-in-a-lifetime. You can do it from your own home. We have introduced it at Rs. 6499 for over 165 drugs, which is probably the lowest price."